ArticleEuropean journal of pharmacology2007
Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.
Article in European journal of pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- The endocannabinoid 2-arachidonoylglycerol mediates seasonal life-history transitions in a wild reptile.The Journal of experimental biology · 2026Article
- Early life outcomes of prenatal exposure to alcohol and synthetic cannabinoids in mice.Drug and alcohol dependence reports · 2025Article
- Article
- Cannabidiol modulation of oxidative stress and signalling.Neuronal signaling · 2021Review
- The nAChR Chaperone TMEM35a (NACHO) Contributes to the Development of Hyperalgesia in Mice.Neuroscience · 2021Article
- Heme Causes Pain in Sickle MiceAntioxidants & redox signaling · 2021Article
- Human carbonic anhydrase-8 AAV8 gene therapy inhibits nerve growth factor signaling producing prolonged analgesia and anti-hyperalgesia in mice.Gene therapy · 2018Article
- Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.The Journal of pharmacology and experimental therapeutics · 2017Article
- Use of Animal Models in Understanding Cancer-induced Bone Pain.Cancer growth and metastasis · 2015Review
- Carbonic anhydrase-8 regulates inflammatory pain by inhibiting the ITPR1-cytosolic free calcium pathway.PloS one · 2015Article
- The neurobiology of cancer pain.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2014Review
- Cannabinoids as therapeutic agents in cancer: current status and future implications.Oncotarget · 2014Review
- The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.Neuroscience · 2013Article
- Pharmacological effects of cannabinoids on the reference and working memory functions in mice.Psychopharmacology · 2013Article
- Enhanced excitability of small dorsal root ganglion neurons in rats with bone cancer pain.Molecular pain · 2012Article
- Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness.British journal of haematology · 2012Article
- The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.Indian journal of urology : IJU : journal of the Urological Society of India · 2012Article
- CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.Behavioural pharmacology · 2011Article
- The endocannabinoid system and cancer: therapeutic implication.British journal of pharmacology · 2011Review
- Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain.Pharmacological research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Patients with cancer frequently report pain that can be difficult to manage. This study examined the antihyperalgesic effects of a cannabinoid receptor agonist, CP 55,940, in a murine model of cancer pain. Implantation of fibrosarcoma cells into and around the calcaneous bone in mice produced mechanical hyperalgesia (decreased paw withdrawal thresholds and increased frequency of paw withdrawals). On day 13 after implantation, mechanical hyperalgesia, nociception, and catalepsy were assessed. Mice were randomly assigned to receive CP 55,940 (0.01-3 mg/kg, i.p.) or vehicle and behavioral measures were redetermined. CP 55,940 dose-dependently attenuated tumor-evoked mechanical hyperalgesia. To examine the effect of catalepsy on the antihyperalgesic effect of CP 55,940, mice with tumor-evoked hyperalgesia were pretreated with the dopamine agonist apomorphine prior to administration of CP 55,940. Apomorphine attenuated the cataleptic effect of CP 55,940 but did not attenuate its antihyperalgesic effect. In a separate group of mice with tumor-evoked hyperalgesia, administration of the dopamine antagonist spiperone produced catalepsy that was approximately 2.5 fold greater than that produced by CP 55,490. Whereas this dose of CP 55,940 completely reversed tumor-evoked mechanical hyperalgesia, spiperone only attenuated mechanical hyperalgesia by approximately 35%. Thus, the cataleptic effects of CP 55,940 did not fully account for its antihyperalgesic effect. The antihyperalgesic effect of CP 55,940 was mediated via the cannabinoid CB1 but not CB2 receptor. Finally, repeated administration of CP 55,940 produced a short-term and a longer-term attenuation of tumor-evoked hyperalgesia. These results suggest that cannabinoids may be a useful alternative or adjunct therapy for treating cancer pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.